Product Pathways - Protein Stability
Cathepsin D Antibody #2284
|2284S||100 µl (10 western blots)||---||In Stock||---|
|2284||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Monkey||Endogenous||46, 43, 28||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IHC-P=Immunohistochemistry (Paraffin), F=Flow Cytometry
Specificity / Sensitivity
Cathepsin D Antibody detects endogenous levels of preprocathepsin D, procathepsin D and the heavy chain subunit of mature cathepsin D.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues with the heavy chain subunit of human Cathepsin D. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from PANC1, SNB19 and MCF-7 cell lines using Cathepsin D Antibody.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using Cathepsin D Antibody.
Immunohistochemical analysis of paraffin-embedded human Non-Hodgkin's lymphoma using Cathepsin D Antibody.
Immunohistochemical analysis of paraffin-embedded human papillary carcinoma using Cathepsin D Antibody.
Immunohistochemical analysis of paraffin-embedded human serous adenocarcinoma using Cathepsin D Antibody.
Flow cytometric analysis of MCF-7 cells using Cathepsin D Antibody (blue) compared to a nonspecific negative control antibody (red).
Cathepsin D is a ubiquitously expressed lysosomal aspartyl protease involved in the normal degradation of proteins (1). It is synthesized as an inactive 43 kDa preprocathepsin D that is cleaved and glycosylated to form a 46 kDa procathepsin D and then further cleaved to produce 28 kDa and 15 kDa subunits (heavy and light chains, respectively) (2). Cathepsin D may also be secreted into the cytosol during apoptosis and contribute to cleavage of substrates implicated in the apoptotic pathway (3). Numerous studies have suggested that cathepsin D plays a role in neuronal degradation and malignant transformation, particularily in breast cancer (4-9).
- Faust, P.L. et al. (1985) Proc. Natl. Acad. Sci. USA 82, 4910-4914.
- Erickson, A.H. et al. (1981) J. Biol .Chem. 256, 11224-11231.
- Liaudet-Coopman, E. et al. (2006) Cancer Lett. 237, 167-179.
- Berchem, G. et al. (2002) Oncogene 21, 5951-5955.
- Nomura, T. and Katunuma, N. (2005) J. Med. Invest. 52, 1-9.
- Garcia, M. et al. (1996) Stem Cells 14, 642-560.
- Nogami, M. et al. (2000) Histochem. J. 32, 505-508.
- Nakanishi, H. (2003) Ageing Res. Rev. 2, 367-381.
- Callahan, L.M. et al. Neurobiol. Aging 19, S99-105.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.